IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industri...
09 Novembre 2016 - 5:57PM
Business Wire
Khang & Khang LLP (the “Firm”) announces the filing of a
class action lawsuit against Teva Pharmaceutical Industries Limited
(“Teva” or the “Company”) (NYSE: TEVA). Investors who purchased or
otherwise acquired shares between February 10, 2015 and November 3,
2016 inclusive (the “Class Period”), are encouraged to contact the
Firm prior to the January 5, 2017 lead plaintiff motion
deadline.
If you purchased Teva shares during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von
Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
The complaint alleges that Teva made false and/or misleading
statements and/or failed to disclose that: Teva engaged in conduct
that would result in a Department of Justice (“DOJ”) antitrust
investigation; that the DOJ investigation and the underlying
conduct could cause U.S. prosecutors to file criminal charges
against the Company by the end of 2016 for suspected price
collusion; that Teva lacked effective internal controls; and that
as a result of the above, the Company’s public statements were
materially false and misleading at all relevant times. On November
3, 2016, Bloomberg News reported that the Justice Department is
conducting an antitrust investigation of over a dozen companies,
including Teva, to determine whether they unlawfully colluded with
each other to fix generic drug prices. When this information was
disclosed to the public, shares of Teva dropped in value.
If you wish to learn more about this lawsuit, or if
you have questions concerning this notice or your rights, please
contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161109005885/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024